Trial Profile

Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenofovir alafenamide (Primary)
Indications Hepatitis B
Focus Therapeutic Use

Most Recent Events

22 Oct 2024 According to a Gilead Sciences, Inc. media release , data from this study will be presented at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif.
15 Nov 2020 Planned End Date changed from 30 Sep 2021 to 30 Sep 2023.
15 Nov 2020 Planned primary completion date changed from 30 Sep 2021 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com